Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 12, 1999, Pages 2759-2766

  Mourier, Nicolas S ^a,b   Eleuteri, Alessandra ^a,b   Hurwitz, Selwyn J ^a,b   Tharnish, Phillip M ^a,b   Schinazi, Raymond F ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Antiviral activity; Boron neutron capture therapy; L Nucleosides

Indexed keywords

5 (2 CARBORAN 1 YL) 2' DEOXYURIDINE; 5 (2 CARBORANYL)PYRIMIDINE NUCLEOSIDE; CARBORANE DERIVATIVE; CYCLOHEXIMIDE; FLUOROURACIL; HETEROCYCLIC COMPOUND; HYDROXYL GROUP; NUCLEOSIDE; PYRIMIDINE NUCLEOSIDE; SUGAR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CATALYST; CHEMICAL REACTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BINDING; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPOPHILICITY; LYMPHOBLASTOID CELL LINE; NEUTRON; NEUTRON CAPTURE THERAPY; NONHUMAN; PHOSPHORYLATION; SERUM; STEREOCHEMISTRY;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PYRIMIDINE NUCLEOTIDES; RATS; STEREOISOMERISM; TUMOR CELLS, CULTURED;

EID: 0033379535     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00222-9     Document Type: Article

References (25)

1. Hawthorne F.M. Angew. Chem. Int. Ed. Engl. 32:1993;950.
2. Soloway A.H., Tjarks W., Barnum B.A., Rong F.-G., Barth R.F., Codogni I.M., Wilson J.G. Chem. Rev. 98:1998;1515.
3. Barth R.F., Soloway A.H., Fairchild R.G., Brugger R.M. Cancer. 70:1992;2995.
4. Fairchild R.G., Bond V.P. Int. J. Radiat. Oncol. Biol. Phys. 21:1985;831.
5. Zamenhof R.G., Kalend A.M., Bloomer W.D. J. Natl. Cancer Inst. 84:1992;1290.
6. Yamamoto, Y.; Seko, T.; Nakamura, H.; Nemoto, H.; Hojo, H.; Mukaoi, N.; Hashimoto, Y. J. Chem. Soc., Chem. Commun. 1992, 157.
7. Schinazi R.F., Goudgaon N.M., Fulcrand G., El Kattan Y., Lesnikowski Z., Ullas G., Moravek J., Liotta D.C. Int. J. Radiat. Oncol. Biol. Phys. 28:1994;1113.
8. Fulcrand-El Kattan G., Goudgaon N.M., Ilksoy N., Huang J.T., Watanabe K.A., Sommadossi J.-P., Schinazi R.F. J. Med. Chem. 37:1994;2583.
9. Shewach D.S., Liotta D.C., Schinazi R.F. Biochem. Pharmacol. 45:1993;1540.
10. Schinazi R.F., Chu C.K., Peck A., McMillan A., Mathis R., Cannon D., Jeong L.-S., Beach J.W., Choi W.-B., Yeola S., Liotta D.C. Antimicrob. Agents Chemother. 36:1992;672.
11. Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M., Peck A., Sommadossi J.-P., St Clair M., Wilson J., Furman P.A., Painter G., Choi W.-B., Liotta D.C. Antimicrob. Agents Chemother. 36:1992;2423.
12. Sommadossi J.-P., Schinazi R.F., Chu C.K., Xie M.-Y. Biochem. Pharmacol. 44:1992;1921.
13. Goudgaon N.M., El Kattan Y., Xia X., McAtee J., Soria J., Wey S.-J., Liotta D.C., Schinazi R.F. Nucleosides and Nucleotides. 16:1997;2133.
14. Kim H.O., Ahn A.J., Alves S.K., Beach J.W., Jeong L.S., Choi B.G., Van Roey P., Schinazi R.F., Chu C.K. J. Med. Chem. 35:1992;1987.
15. Vorbrüggen H., Hofle G. Chem. Ber. 114:1981;1256.
16. Graciet J.-C., Shi J., Schinazi R.F. Nucleosides and Nucleotides. 17:1998;711.
17. Shi J., McAtee J.J., Wirtz S.S., Tharnish P.M., Juodawlkis A., Liotta D.C., Schinazi R.F. J. Med. Chem. 42:1999;859.
18. Holý A. Tet. Lett. 2:1971;189.
19. Hampton A., Nichol A.W. Biochemistry. 5:1966;2076.
20. Schinazi R.F., Chen M.S., Prusoff W.H. J. Med. Chem. 22:1979;1273.
21. Fulcrand-El Kattan G., Lesnikowski Z.J., Yao S., Tanious F., Wilson W.D., Schinazi R.F. J. Am. Chem. Soc. 116:1994;7494.
22. Schinazi R.F., Sommadossi J.-P., Saalman V., Cannon D.L., Xie M.-Y., Hart G.C., Smith G.A., Hahn E.F. Antimicrob. Agents Chemother. 34:1990;1061.
23. Chou T.C., Talalay P. Adv. Enzyme Regul. 22:1984;27.
24. Belen'kii, M. S.; Schinazi, R. F. Antiviral Res. 1994, 25,1.
25. Hurwitz S.J., Terashima M., Mizunuma N., Slapak C.A. Blood. 89:1997;3745.